This site is intended for health professionals only

At the heart of general practice since 1960

pul jul aug2020 cover 80x101px
Read the latest issue online

Independents' Day

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Your comments will be sent to our moderator for review.

Report comment to moderator

Required fields.

Headline

NICE recommends 'game-changing' heart failure drug

Comment

PARADIGM-HF trial: Sacubitril (blocks the enzyme ,neprilysn , which in turn,breaks down BNP and ANP). Together with valsartan(LCZ696)versus enalapril: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P

Posted date

27 Apr 2016

Posted time

1:07pm

required
required
required